Anticonvulsants Market Report 2026

Anticonvulsants Market Overview

• Anticonvulsants market size has reached to $19.25 billion in 2025 • Expected to grow to $23.4 billion in 2030 at a compound annual growth rate (CAGR) of 4.1% • Growth Driver: The Surge In Epilepsy Cases Drives Growth In The Anticonvulsants Market • Market Trend: Advancements In Anticonvulsant Therapies Expand Treatment Options For Rare Seizure Disorders • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Anticonvulsants Market?

Anticonvulsants, also called anti-seizure medication and antiepileptics, refer to a type of drug or medication used to prevent and treat seizures or convulsions by controlling abnormal electrical activity in the brain. This medication is used to treat conditions such as nerve pain and restless leg syndrome. The main types of anticonvulsants include pyrimidinediones, fructose derivatives, aromatic allylic alcohols, valproylamides, carboxamides, bromides and others. Pyrimidine refers to a heterocyclic aromatic organic compound that serves as a component of nucleic acids (such as DNA and RNA), certain proteins, starches, and others. These drugs are generated by the first-generation, second generation and third-generations and consumed in dosage forms of capsules, tablets, liquids, rectal gel and others for applications in migraine, epilepsy, neuropathic pain, anxiety, fibromyalgia, bipolar disorder, borderline personality disorder. These are used in various end-user industries such as hospitals, clinics and others.

What Is The Anticonvulsants Market Growth Forecast?

The anticonvulsants market size is expected to see steady growth in the next few years. It will grow to $23.4 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to increasing adoption of precision medicine, growth in geriatric population, expansion of outpatient care facilities, rise in R&D for combination therapies, digital health integration in epilepsy management. Major trends in the forecast period include personalized anticonvulsant therapy, development of novel drug delivery systems, growth in geriatric epilepsy population, expansion of outpatient neurology services, increasing use of combination therapies.

What Is The Driver Of The Anticonvulsants Market?

The rise in the prevalence of epilepsy is expected to propel the growth of the anticonvulsants market going forward. Epilepsy is a common disorder that affects the brain and frequently results in seizures. It is a chronic nontransmissible disease of the brain that affects people of all ages. Anticonvulsants are medications used to suppress seizures in people with epilepsy. Anticonvulsants help control symptoms of epilepsy by blocking the abnormal electrical activity in the brain that causes seizures and are not necessarily a cure for the disease. For instance, in February 2023, according to the World Health Organization, a Switzerland-based United Nations agency responsible for public health, globally, an estimated 5 million people are diagnosed with epilepsy yearly. The high-income countries have an estimated 49 per 0.1 million people are diagnosed with epilepsy each year, and as many as 139 per 0.1 million in low- and middle-income countries. Therefore, the rise in the prevalence of epilepsy is driving the growth of the anticonvulsants industry.

Key Players In The Global Anticonvulsants Market

Major companies operating in the anticonvulsants market are Eisai Co Ltd., GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services Inc., Novartis AG, Jazz Pharmaceuticals Inc., UCB SA, Teva Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals Inc., Sanofi SA, Zydus Lifesciences Ltd., Lupin Limited, Ratiopharm Group, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Mylan N.V., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals plc, Glenmark Pharmaceuticals Limited, Laurus Labs Limited, Recordati S.p.A., Neurocrine Biosciences Inc.

Global Anticonvulsants Market Trends and Insights

Major companies operating in the anticonvulsants market are focusing on developing innovative drug solutions and securing regulatory approvals to address unmet needs in seizure management and strengthen their competitive position. Novel anticonvulsant therapies aim to enhance treatment efficacy for patients with seizures associated with rare and severe syndromes. For instance, in March 2024, the Medicines and Healthcare products Regulatory Agency (MHRA), the UK-based national regulatory authority, approved ganaxolone (Ztalmy) as the first anti-seizure medication for the treatment of seizures linked to cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder. Ganaxolone, a neuroactive steroid, provides a novel therapeutic option for this challenging epileptic encephalopathy, targeting hard-to-control seizures and fulfilling a critical unmet need for affected patients.

What Are Latest Mergers And Acquisitions In The Anticonvulsants Market?

In January 2023, Catalyst Pharmaceuticals, a US-based commercial-stage biopharmaceutical company, acquired U.S. rights of FYCOMPA (Perampanel) CIII from Eisai Co. Ltd for an undisclosed amount. This acquisition FYCOMPA (perampanel) aims to strategically enhance the company's portfolio in the neurology sector, particularly focusing on epilepsy treatment. FYCOMPA (perampanel) CIII is a prescription medication used for the treatment of epilepsy, specifically indicated for partial-onset seizures. Eisai Co. Ltd is a Japan-based pharmaceutical company manufactures anticonvulsant drugs.

What Defines the Anticonvulsants Market?

The anticonvulsant market consists of sales of drugs such as phenobarbital, phenytoin, carbamazepine, levetiracetam, ethosuximide, clonazepam, diazepam, lorazepam, and midazolam. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anticonvulsants Market Report 2026?

The anticonvulsants market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anticonvulsants industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.